<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820116</url>
  </required_header>
  <id_info>
    <org_study_id>RIPOT1606</org_study_id>
    <nct_id>NCT02820116</nct_id>
  </id_info>
  <brief_title>The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation</brief_title>
  <official_title>An Open-label, Multicenter，Single-arm, Phase II Clinical Study of Icotinib for IIIA - IIIB NSCLC Patients With Epidermal Growth Factor Receptor Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Haidian Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>307 Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>309th Hospital of Chinese People's Liberation Army</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Haidian Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, single-arm, phase II interventional clinical trial&#xD;
      evaluating efficacy and safety of Icotinib as neoadjuvant treatment in patients with IIIA-&#xD;
      IIIB NSCLC with activating EGFR mutation in exon 19 or 21. Sixty-seven resectable stage IIIA-&#xD;
      IIIB NSCLC patients with EGFR activating (19/21) mutations will be eligible to be enrolled.&#xD;
      EGFR mutation will be prospectively tested in all the participants' biopsy samples and&#xD;
      confirmed in surgical resected samples.&#xD;
&#xD;
      Neoadjuvant treatment phase:&#xD;
&#xD;
      Eligible patients will receive 125mg of Icotinib three times per day. Treatment will be&#xD;
      scheduled to continue until the disease progression or unbearable toxicities appear.&#xD;
&#xD;
      Surgery treatment phase:&#xD;
&#xD;
      Tumor response will be evaluated with CT scan after 8 weeks of induction treatment. The&#xD;
      patients with responsive disease considered to be technique resectable will undergo&#xD;
      resection.&#xD;
&#xD;
      Post-surgery phase:&#xD;
&#xD;
      It is the discretion of the investigator whether the patient is a candidate for&#xD;
      post-operative treatment which is considered to be in the best interest of the patients. It&#xD;
      is recommended that patients with positive margins or residual tumor after surgery should&#xD;
      receive radiation therapy. Patients after surgery will receive long-term follow-up -- chest&#xD;
      CT scan，abdominal abdominal ultrasound every 3 months, brain MRI every 6 months, bone scan&#xD;
      (ECT) every 12 months -- for up to 5 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete resection rate</measure>
    <time_frame>Complete resection rate is depended on the pathology diagnosis after surgery, an expected average of 8 weeks from enrollment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate(ORR, i.e., complete response [CR] + partial response [PR])</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (CR + PR+ stable disease)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical down-staging</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Participants after surgery will receive long-term follow-up for up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Participants after surgery will receive long-term follow-up for up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Event</measure>
    <time_frame>Within 28 days of last study dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Non-small Cell Lung Cancer(NSCLC)</condition>
  <arm_group>
    <arm_group_label>Icotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Icotinib PO TID for 8 weeks and then undergo thoracotomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icotinib</intervention_name>
    <description>In the neoadjuvant treatment phase, eligible patients will receive 125mg of Icotinib three times per day for 8 weeks (56 days). In the post-surgery phase, Icotinib 125mg/three tims/day taken orally for 2 years or till disease progression or unacceptable toxicity.</description>
    <arm_group_label>Icotinib</arm_group_label>
    <other_name>Conmana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of informed consent&#xD;
&#xD;
          2. Pathologically confirmed non-small cell lung cancer with EGFR exon 19 deletion or exon&#xD;
             21 L858 mutation.&#xD;
&#xD;
          3. Clinically or pathologically confirmed stage IIIA- IIIB&#xD;
&#xD;
          4. Tolerable to complete resection of lung cancer&#xD;
&#xD;
          5. Able to comply with the required protocol and follow-up procedures, and able to&#xD;
             receive oral medications&#xD;
&#xD;
          6. ECOG performance status 0-1.&#xD;
&#xD;
          7. Life expectancy ≥12 weeks.&#xD;
&#xD;
          8. Measurable disease must be characterized according to RECIST 1.1 criteria. Measurable&#xD;
             lesions are defined as those that can be accurately measured in at least one dimension&#xD;
             as ≥ 10mm by spiral CT scan.&#xD;
&#xD;
          9. Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109/L, and&#xD;
             Platelet count ≥100 x 109/L, and Hemoglobin ≥10 g/dL (may be transfused to maintain or&#xD;
             exceed this level).&#xD;
&#xD;
         10. Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN);&#xD;
             Aspartate amino transferase (AST) and alanine amino transferase (ALT) ≤ 2.5 x upper&#xD;
             limit of normal (ULN).&#xD;
&#xD;
         11. Adequate renal function: Serum creatinine ≤ 1.25 x upper limit of normal (ULN), and&#xD;
             creatinine clearance≥ 60 ml/min.&#xD;
&#xD;
         12. Measurable disease according to the preset criteria .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with prior exposure to chemotherapy, irradiation or systemic anti-cancer&#xD;
             therapy (e.g. monoclonal antibody therapy) for lung cancer.&#xD;
&#xD;
          2. Known severe hypersensitivity to Icotinib or any of the excipients of this product&#xD;
&#xD;
          3. Previous or current malignancies of other histologies within the last 5 years with the&#xD;
             exception of the following: other malignancies cured by surgery alone and having a&#xD;
             continuous disease-free survival of 5 years; cured basal cell carcinoma of the skin&#xD;
             and cured in situ carcinoma of the uterine cervix.&#xD;
&#xD;
          4. Any unstable systemic disease (including active infection, uncontrolled hypertension,&#xD;
             unstable angina, congestive heart failure, myocardial infarction within six months,&#xD;
             serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic&#xD;
             disease).&#xD;
&#xD;
          5. Interstitial lung disease(ILD) or pulmonary fibrosis; impaired pulmonary function.&#xD;
&#xD;
          6. Eye inflammation or eye infection not fully treated or predisposing factor of this.&#xD;
&#xD;
          7. Uncontrolled central nervous system (CNS) metastasis.&#xD;
&#xD;
          8. Any serious concomitant systemic disorder that, in the opinion of the investigator,&#xD;
             would compromise the patient's ability to complete the study&#xD;
&#xD;
          9. Evidence of any other disease, neurological or metabolic dysfunction, physical&#xD;
             examination or laboratory finding giving reasonable suspicion of a disease or&#xD;
             condition that contraindicates the use of an investigational drug or puts the subject&#xD;
             at high risk for treatment-related complications.&#xD;
&#xD;
         10. Pregnancy or breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun liu, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuqing Huang, doctor</last_name>
    <phone>+8601082693152</phone>
    <email>huangyuqing555@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun liu, doctor</last_name>
    <phone>+8601082693152</phone>
    <email>liujundaifu@yahoo.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Haidian Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuqing Huang, Doctor</last_name>
      <phone>+8601082693152</phone>
      <email>huangyuqing555@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Haidian Hospital</investigator_affiliation>
    <investigator_full_name>Huang Yuqing</investigator_full_name>
    <investigator_title>Deputy Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

